Cannabis-Based Drug Companies Hopeful Epidiolex Will Pave the Way for Future Approvals

Following the U.S. Drug Enforcement Agency’s rescheduling of GW Pharmaceuticals' Epidiolex from a Schedule I to a Schedule V, other cannabis-based drug development companies believe there is momentum for their medications to gain regulatory approval.